Thomas Christopher A, Taylor Kathryn, Schamberger Marcus S, Rotta Alexandre T
Congenit Heart Dis. 2014 Jul-Aug;9(4):361-5. doi: 10.1111/chd.12151.
To determine the incidence of supratherapeutic international normalized ratio (INR) values in patients initiated on warfarin in the pediatric intensive care unit after the Fontan procedure.
Retrospective chart review.
Pediatric intensive care unit in a freestanding pediatric teaching hospital.
Thirty-two consecutive children with single ventricle physiology with an initial Fontan conversion. All were initiated on warfarin in the postoperative period while in the intensive care unit.
Supratherapeutic INR values, interventions in warfarin dosing to address or prevent supratherapeutic INR values, major and minor bleeding episodes, and venous thromboembolic events.
Supratherapeutic INR values after warfarin initiation occurred in 12.5% (n = 4) of patients with an additional 6.3% (n = 2) requiring dose adjustments due to a rapidly increasing INR. Patients with a supratherapeutic INR were started on warfarin earlier compared with other patients (median postoperative day 2 vs. 5, P = .037, respectively). There were no reported thrombi or thromboembolic events and the only clinically significant bleeding event occurred while the INR value was subtherapeutic.
Patients undergoing the Fontan procedure may be more sensitive to warfarin dosing when initiated closer to the surgical procedure date. Despite this observation, warfarin appears to be a safe medication for use within the early postoperative period after the Fontan procedure when response to therapy is monitored closely. Clinicians should use caution when initiating warfarin before postoperative day 3 in patients undergoing an initial Fontan operation.
确定在小儿重症监护病房接受Fontan手术的患者中,华法林起始治疗后国际标准化比值(INR)超治疗范围值的发生率。
回顾性病历审查。
一家独立的儿科教学医院的小儿重症监护病房。
32例连续的单心室生理患儿,首次进行Fontan转换手术。所有患儿在重症监护病房术后均开始使用华法林治疗。
INR超治疗范围值、为处理或预防INR超治疗范围值而进行的华法林剂量调整、严重和轻微出血事件以及静脉血栓栓塞事件。
华法林起始治疗后,12.5%(n = 4)的患者出现INR超治疗范围值,另有6.3%(n = 2)的患者因INR迅速升高需要调整剂量。与其他患者相比,INR超治疗范围值的患者更早开始使用华法林(术后中位天数分别为2天和5天,P = 0.037)。未报告血栓或血栓栓塞事件,唯一具有临床意义的出血事件发生在INR值低于治疗范围时。
在Fontan手术日期附近开始使用华法林时,接受Fontan手术的患者可能对华法林剂量更敏感。尽管有此观察结果,但在密切监测治疗反应的情况下,华法林似乎是Fontan手术后早期使用的安全药物。对于首次接受Fontan手术的患者,临床医生在术后第3天之前开始使用华法林时应谨慎。